Acta paediatrica (Oslo, Norway : 1992) · 2026
Rationale for Recommending Varicella Vaccination Into the Swedish National Immunisation Programme.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ersson Annika, Johansen Kari, Andersson Sören
Аннотация
AIM: Under Swedish law, a vaccination may be included in the National Immunisation Programme (NIP) if it effectively prevents transmission in the population, is cost-effective and aligns with ethical and humanitarian principles. The Public Health Agency of Sweden (PHAS) evaluated these criteria for introducing varicella vaccination.
METHODS: The evaluation included a literature review, disease modelling to assess dose timing, a health economic analysis and an ethical review addressing vaccine acceptance and equitable access.
RESULTS: Varicella vaccines are safe and highly effective, providing near-complete protection against severe disease requiring hospitalisation when two doses are given. Modelling indicates that virus circulation could be eliminated within 2-3 years with high coverage and catch-up vaccination, also protecting unvaccinated and immunocompromised individuals of all ages through population immunity. Two doses are recommended at 18 months and 7-8 years, both co-administered with MMR. This schedule ensures durable immunity and high acceptance. Health economic analyses show the programme would be cost saving.
CONCLUSION: Following PHAS's evaluation, the Swedish government has decided to include varicella vaccination in the NIP from 2027, with catch-up vaccination for susceptible individuals up to 18 years, implemented primarily through the child and school health services to ensure equitable access.
METHODS: The evaluation included a literature review, disease modelling to assess dose timing, a health economic analysis and an ethical review addressing vaccine acceptance and equitable access.
RESULTS: Varicella vaccines are safe and highly effective, providing near-complete protection against severe disease requiring hospitalisation when two doses are given. Modelling indicates that virus circulation could be eliminated within 2-3 years with high coverage and catch-up vaccination, also protecting unvaccinated and immunocompromised individuals of all ages through population immunity. Two doses are recommended at 18 months and 7-8 years, both co-administered with MMR. This schedule ensures durable immunity and high acceptance. Health economic analyses show the programme would be cost saving.
CONCLUSION: Following PHAS's evaluation, the Swedish government has decided to include varicella vaccination in the NIP from 2027, with catch-up vaccination for susceptible individuals up to 18 years, implemented primarily through the child and school health services to ensure equitable access.